IPO Timeline Raw facts
Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading
Company Overview
| Stock Name | Transthera-B |
|---|---|
| Stock Code | 02617 |
| Company Full Name | TransThera Sciences (Nanjing), Inc. |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家以臨床需求為導向、處于注冊臨床階段的生物制藥公司,專注于發現及開發腫瘤、炎癥及心臟代謝疾病小分子創新療法。 |
| Listing Date | 2025-06-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省南京市江北新區生物醫藥谷加速器二期9棟3樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.transthera.com/En/Index/index |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 13.15 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2025-06-13 to 2025-06-18 |
| Global Offering Shares | 15,281,000 shares |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 64.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 200,945,150 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 10.87B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | RMB 569.5 million |
| Listing Expenses | ~HK$ 36,300,000 |
| Listing Expenses / Funds Raised | ~19.7% |
| Total Pre-IPO Investment | approximately RMB 1,723 million |
| First Day Close | HK$ 23.5 |
|---|---|
| First Day Open | HK$ 21.65 |
| First Day Change | 78.71% |
| First Day Volume | 8541000.0 |
| First Day Turnover | 191298000.0 |
| Use of Proceeds | 1、約90.0%或145.2百萬港元將用于為我們的核心產品Tinengotinib正在進行單藥治療CCA的多區域注冊III期臨床試驗提供資金;
2、約10.0%或16.1百萬港元將分配用于我們的一般營運資金及一般公司用途。 |
Underwriting Syndicate
Sponsor cum Overall Coordinator (2)
Overall Coordinators (3)
Joint Global Coordinators (3)
Joint Bookrunners (7)
Joint Lead Managers (7)
Capital Market Intermediaries (7)
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
美迈斯律师事务所 嘉源律师事务所 |
| Legal Advisor to Sponsors/Underwriters |
盛德律师事务所 竞天公诚律师事务所 |
| Auditor and Reporting Accountant | 安永会计师事务所 |
| Industry Advisor | 弗若斯特沙利文(北京)咨询有限公司上海分公司 |
| Receiving Banks |
招商永隆银行有限公司 中国银行(香港)有限公司 |
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 华盛敦行有限公司 | 21,592,300 HKD | — | 10.75% | — | 6 months | 2025-12-23 |
| 2 | 江北医药科技(香港)有限公司 | 75,487,575 HKD | — | 37.57% | — | 6 months | 2025-12-23 |
| 3 | 康方生物科技(开曼)有限公司 | 9,895,375 HKD | — | 4.92% | — | 6 months | 2025-12-23 |
| 4 | 科瓴安(香港)科技有限公司 | 10,750,125 HKD | — | 5.35% | — | 6 months | 2025-12-23 |
| 5 | 药石地平线资本有限公司 | 10,802,725 HKD | — | 5.38% | — | 6 months | 2025-12-23 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 吳永謙 | — |
| Company Secretary | 馮潔,黃荻 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 南京益鏷生物科技合伙企業(有限合伙)(13.79%),吳永謙(12.06%),南京吉旻瑞生物科技合伙企業(有限合伙)(7.13%),基科發展有限公司(6.96%),先進制造產業投資基金二期(有限合伙)(6.12%) |
|---|




